Access Pharma After Europe… North American Strategy Revealed
Posted by Tom Allinder on Wed, Jul 29, 2009 @ 10:09 AM
In a press release today, Access Pharmaceuticals (OTCBB: ACCP) announced today that it is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy, and previously announced data suggest that the market for MuGard is significantly greater than previously expected. Frank Jacobucci, formerly President & CEO of Milestone Biosciences, has joined Access as a consultant, and will assist with ongoing reimbursement, manufacturing and commercial launch activities at Access, while discussions with potential licensee and co-promotion partners is ongoing.
“Access is focused on maximizing the potential of MuGard, both for patients and for its shareholders,” states Jeffrey B. Davis, Access’ President & CEO. “Bringing MuGard back in-house will enable Access to capture more of MuGard’s value for shareholders, and be more intimately involved in the ongoing commercialization activities. I welcome the expert insight and experience of Frank Jacobucci, who brings great knowledge and expertise in launching pharma products, with a particular expertise in oral mucositis and related indications, and of course MuGard.”
Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.
“I have always known the substantial potential for MuGard in the prevention and treatment of oral mucositis as well as it being very important for the medical community, and an exciting commercial opportunity in the pharma sector,” stated Frank Jacobucci. “I look forward to working with the Access team while preparing for a MuGard launch in North America and bringing additional pharma resources to bear as needed. These efforts will not only maximize the potential for MuGard but, more importantly, provide access and availability for patients; thus improving outcomes I continue to believe that MuGard is a very important product for the cancer community, as the negative impact of oral mucositis on patient health and treatment is very significant.”
See our Disclaimer Page